Has iBio Pharma (IBIO) Dropped the Ball compared to Aytu Bioscience (AYTU) in the Race to Establish themselves as Leaders in COVID-19 Competition.

investingbulletin

There are numerous companies currently that are in a race to establish either shorter testing deltas, as well as a vaccine, such as AbbVie (NYSE:ABBV), Moderna (NASDAQ:MRNA), Regeneron (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD). For example, so far in the United States, more than 40,000 people have been infected and as community spread rises, health care officials are looking for faster and proper assessment solutions to isolate the infected. A number of mid-to-large cap companies are beginning to establish a strong footing in the race, such as iBio (NYSEMKT:IBIO) and Aytu BioScience (NASDAQ:AYTU).

However, as the weeks go on analysts have more time to analyze which company, IBIO vs AYTU, has what it takes to keep up with the immense momentum needed to survive the virus-affected global markets. It now appears that ultimately, the coronavirus isn’t a sustainable business model for iBio. And unlike biotechnology giants and COVID-19 competitors Gilead Sciences (NASDAQ:GILD) and Regeneron (NASDAQ:REGN), the stock isn’t well-positioned to move beyond this disease.

To be fair, IBIO stock’s dangling coronavirus carrot could prove a quick windfall for the company, if in fact it finds a vaccine which works. But as InvestorPlace’s Luke Lango points out, COVID-19 is still a one-off event. It’s also important to be mindful of overzealous self-promotion on Wall Street. And by my count, since iBio shares were first plucked out of obscurity last month, the bulk of reporting has been press releases alerting investors to iBio’s potential.

Source: https://investorplace.com/2020/03/its-time-for-investors-to-run-far-away-from-ibio-stock/

Aytu BioScience (NASDAQ:AYTU) has received confirmation from the FDA to begin distribution of its COVID-2019 IgG/IgM Rapid Test throughout the U.S. The test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care. The company expects delivery of its first shipment of 100,000 tests this week.This point-of-care test has been validated in a 126 patient clinical trial and is CE marked, with an above average STR value (meaning a high probability test)

Now, analysts have given Aytu BioScience (NASDAQ:AYTU) a buy-status upgrade, which is rare for a company so soon after multiple offerings. However, the company has surpassed the majority of CoronaVirus related stocks, as it is now in the lead for testing solutions.

Connecting to recent Stem Cell studies on COVID-19, a new report out shows that Bio-Pharm companies have shifted their focus from CX pathology systems (what has typically been for Coronovirus) to research on the effect of Stem Cell differentiation on the Corona Virus.

Chinese doctor who runs a lab in Wuhan – ground zero of the coronavirus pandemic – claims he could save thousands of lives after making a breakthrough in the treatment of the deadly pathogen, DailyMailTV can reveal. Dr. Dongcheng Wu, an expert in stem cell therapy, said he has successfully treated nine patients who were hospitalised with novel coronavirus pneumonia.

https://www.dailymail.co.uk/news/article-8116881/Doctor-claims-breakthrough-stem-cell-injections-treat-coronavirus.html

Fresh off a successfully reverse merger, and FINRA approved name and ticker change, StemSation International Inc OTCMKTS:STSN just announced a major expansion in R&D to the Stem Cell system of the body, and ways to create products to boost this systems responsivenes. The company is attempting to push from the USA into other markets with their advanced stem cell system (SCS) renewal and repair and the endocannabinoid system (ECS) products.

Since the reverse merger, there is only 1.1 million in the company float, making it a ultra-low float stock. Furthermore, there is now a website launched by the company along with a number of social media sites. With such a small float, a return to the $1.00 trading range is now possible now that the reverse merger is complete, and the company has begun rolling out its new products.

Hard hitting CEO Ray Carter Jr., who was responsible for growing the company StemTech to $65 million, has announced he is now the CEO of StemSation International Inc (OTC:STSN). For over 30 years, Ray has directed growth in both private and public direct selling companies, from start-ups to Fortune 500 firms. His new company, StemSation International Inc (OTC:STSN) has just launched, and is now trading OTC Pink current under the symbol “STSN“.

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Aurora Cannabis (ACB) Poised for Significant Boost following Canada's Massive Stimulus Package Rollout; Along with other Cannabis Companies.

Aurora Cannabis & Integrated Cannabis Solutions are poised to enter the second quarter with high than expected price projections. Aurora Cannabis ( TSE:ACB) has had a rough start to 2020, with analyst after analyst taking hits at the struggling stock. A variety of factors are to blame for this, both within and […]

Subscribe US Now